NASHVILLE, Tenn., Nov. 13, 2020 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (Nasdaq: SDC), the oral care company with the first medtech platform for teeth straightening, today announced that management will attend two upcoming conferences on Wednesday, November 18th, including the Stifel Virtual Healthcare Conference and the Wolfe Virtual Healthcare Conference.
Stifel Virtual Healthcare Conference
Wolfe Virtual Healthcare Conference
The audio portions of these presentations will be webcast live and can be accessed in the “Events and Presentations” section at https://investors.smiledirectclub.com.
About SmileDirectClub
SmileDirectClub, Inc. (Nasdaq: SDC) (“SmileDirectClub”) is an oral care company and creator of the first medtech platform for teeth straightening, now also offered directly via dentist and orthodontists’ offices. Through its cutting-edge teledentistry technology and vertically integrated model, SmileDirectClub is revolutionizing the oral care industry, from clear aligner therapy to an affordable, premium oral care product line. SmileDirectClub’s mission is to democratize access to a smile each and every person loves by making it affordable and convenient for everyone. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Australia, New Zealand, United Kingdom, Ireland, Germany, Austria, Hong Kong, Singapore and Spain. For more information, please visit SmileDirectClub.com.
Contact:
SmileDirectClub Media Relations: Press@SmileDirectClub.com
SmileDirectClub Investor Relations: Investors@SmileDirectClub.com
New multilingual capabilities expand access to real-time GLP-1 dining guidance as WHO highlights the importance…
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…